Our research found that TEFT inhibits the TGF‐β signaling pathway, reducing phosphorylation of SMAD2/3 and STAT3, thereby suppressing C1R expression and resulting in weakened EMT and invasive capabilities of GBM. The gene discussed is SMAD2; the disease is glioblastoma.